Casirivimab and imdevimab in patients admitted to hos randomised, controlled, open-label, platform trial

Lancet, The

399, 665-676

DOI: 10.1016/s0140-6736(22)00163-5

Citation Report

#	Article	IF	Citations
1	The Airway Microbiome: Present and Future Applications. Archivos De Bronconeumologia, 2022, 58, 8-10.	0.8	19
2	Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes. Clinical Infectious Diseases, 2022, 74, 1525-1533.	5.8	96
3	Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease. Lancet Respiratory Medicine,the, 2021, 9, 947-949.	10.7	3
4	One year on: The impact of COVID-19 on clinical research. European Journal of Internal Medicine, 2021, 92, 24-27.	2.2	2
5	Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infectious Diseases, The, 2021, 21, 1345-1347.	9.1	26
6	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. Cardiology in Review, 2022, 30, 145-157.	1.4	11
7	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 2022, 91, 89-100.	5.3	119
8	Colchicine treatment in COVID-19: the remaining unsolved question. Lancet Respiratory Medicine,the, 2021, 9, 1351-1353.	10.7	1
9	What went wrong: A reckoning of Canadaâ€™s contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic. Jammi, 2021, 6, 241-244.	0.5	2
10	Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. Clinical Infectious Diseases, 2022, 75, e1028-e1036.	5.8	6
11	What does endemic COVID-19 mean for the future of rituximab?. Lancet Rheumatology, The, 2022, 4, e3-e5.	3.9	8
12	Assessing the evidence on remdesivir. Lancet Infectious Diseases, The, 2021, 21, 1630-1631.	9.1	8
13	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, , .	1.3	0
14	Monoclonal SARS-CoV-2 antibodies in pregnancyâ€”a case series. Deutsches Ärzteblatt International, 2022, 119, 113-114.	0.9	2
15	Convalescent plasma for COVID-19. TSUNAMI is not the final word. European Journal of Internal Medicine, 2022, 97, 116-118.	2.2	4
16	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, The, 2022, 399, 530-540.	13.7	48
18	The impact of neutralizing monoclonal antibodies on the outcomes of COVIDâ€19 outpatients: A systematic review and metaâ€analysis of randomized controlled trials. Journal of Medical Virology, 2022, 94, 2222-2229.	5.0	43
19	Three-dose vaccination elicits neutralising antibodies against omicron. Lancet, The, 2022, 399, 715-717.	13.7	82

#	Article	IF	Citations
20	COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. Infectious Disease Clinics of North America, 2022, 36, 397-421.	5.1	7
21	An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102396.	3.6	51
22	SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19. American Journal of Transplantation, 2022, 22, 1316-1320.	4.7	18
23	COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments. Acta Haematologica, 2022, 145, 244-256.	1.4	7
24	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 278-288.	10.7	61
25	Another piece in the COVID-19 treatment puzzle. Lancet, The, 2022, 399, 609-610.	13.7	6
26	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 622-635.	9.1	135
27	SARS-CoV-2â€“neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma. Blood Advances, 2022, 6, 1580-1584.	5.2	8
28	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nature Reviews Rheumatology, 2022, 18, 191-204.	8.0	105
29	Global challenges in preparedness and response to epidemic infectious diseases. Molecular Therapy, 2022, 30, 1801-1809.	8.2	10
30	COVID-19 can be called a treatable disease only after we have antivirals. Science Bulletin, 2022, 67, 999-1002.	9.0	5
31	REGENâ€COV antibody combination in patients with lymphoproliferative malignancies and SARSâ€CoVâ€2 infection. EJHaem, 2022, 3, 471-474.	1.0	4
32	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. Critical Care Clinics, 2022, , .	2.6	3
33	Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings. Clinical Infectious Diseases, 2022, 75, e368-e379.	5.8	4
34	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clinical Microbiology Reviews, 2022, 35, e0020021.	13.6	64
35	Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy. Infection, 2022, , 1.	4.7	4
36	Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant. Viruses, 2022, 14, 650.	3.3	10
37	Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection. European Journal of Internal Medicine, 2022, 100, 137-139.	2.2	0

#	Article	IF	Citations
38	Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study. Antibiotics, 2022, 11, 345.	3.7	15
41	An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants. Transplantation, 2022, 106, 1421-1429.	1.0	7
42	Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. Journal of Infection and Chemotherapy, 2022, 28, 991-994.	1.7	4
43	Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series. Current Oncology, 2022, 29, 2312-2325.	2.2	8
44	Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. Lancet Rheumatology, The, 2022, 4, e154-e155.	3.9	25
46	High-cited favorable studies for COVID-19 treatments ineffective in large trials. Journal of Clinical Epidemiology, 2022, 148, 1-9.	5.0	4
47	Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19. Lancet Infectious Diseases, The, 2022, 22, 567-569.	9.1	9
48	Compassionate Use of REGEN-COVÂ® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders. Clinical Infectious Diseases, 2022, 75, e509-e515.	5.8	8
49	The effect of casirivimab with imdevimab on disease progression in nonsevere COVIDâ€19 patients in a single hospital in Japan. Journal of General and Family Medicine, 2022, 23, 158-163.	0.8	2
50	Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis. Journal of Infection, 2022, 85, e10-e12.	3.3	7
51	The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic. Transplantation, 2022, 106, 1312-1329.	1.0	44
52	New Antivirals and Immune Therapies for COVID-19 Infection. Archivos De Bronconeumologia, 2022, , .	0.8	0
53	Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report. BMC Infectious Diseases, 2022, 22, 362.	2.9	6
54	COVID-19 and kidney disease: insights from epidemiology to inform clinical practice. Nature Reviews Nephrology, 2022, 18, 485-498.	9.6	36
55	Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection. Open Forum Infectious Diseases, 2022, 9, .	0.9	8
57	Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Infection, 2023, 51, 21-35.	4.7	13
58	Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial. SSRN Electronic Journal, 0, , .	0.4	3
59	Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value in Health, 2022, , .	0.3	5

#	Article	IF	Citations
60	Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. Audiology Research, 2022, 12, 224-248.	1.8	6
61	Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series. Kidney Medicine, 2022, 4, 100470.	2.0	11
63	Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infection, 2023, 51, 261-263.	4.7	8
64	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia, 2022, 36, 1467-1480.	7.2	63
65	Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection. Nature Communications, 2022, 13, 2263.	12.8	6
66	Immune treatment in COVID-19. Revista Espanola De Quimioterapia, 2022, 35, 59-63.	1.3	3
67	Convalescent Plasma for Covid-19 â€" Making Sense of the Inconsistencies. New England Journal of Medicine, 2022, 386, 1753-1754.	27.0	22
68	Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. Expert Review of Clinical Immunology, 2022, 18, 557-565.	3.0	10
70	COVID-19â€"from emerging global threat to ongoing pandemic crisis. Baylor University Medical Center Proceedings, 2022, 35, 468-475.	0.5	4
71	Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet, The, 2022, 399, 1941-1953.	13.7	224
72	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	8.2	26
73	Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022, 55, 925-944.	14.3	74
74	Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir. Baylor University Medical Center Proceedings, 0, , 1-3.	0.5	1
75	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	2.1	7
76	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. Viruses, 2022, 14, 1089.	3.3	9
77	Benefitâ€"risk evaluation of COVID-19 vaccination in special population groups of interest. Vaccine, 2022, 40, 4348-4360.	3.8	5
78	Case Report: A Severe Paediatric Presentation of COVID-19 in APDS2 Immunodeficiency. Frontiers in Immunology, 2022, 13, .	4.8	5
79	An Approach to the Treatment of Children With COVID-19. Pediatric Infectious Disease Journal, 2022, 41, 654-662.	2.0	5

#	Article	IF	Citations
80	Laboratory Diagnosis for SARS-CoV-2 Infection. Infectious Disease Clinics of North America, 2022, 36, 327-347.	5.1	4
82	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. Lancet Respiratory Medicine,the, 2022, 10, 700-714.	10.7	22
83	Large scale clinical trials: lessons from the COVID-19 pandemic. BMJ Open Respiratory Research, 2022, 9, e001226.	3.0	7
84	Outcome of infection with omicron <scp>SARSâ€CoV</scp>â€2 variant in patients with hematological malignancies: An <scp>EPICOVIDEHA</scp> survey report. American Journal of Hematology, 2022, 97, .	4.1	39
85	How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 6377.	4.1	7
86	Therapeutics to tackle Omicron outbreak. Immunotherapy, 2022, 14, 833-838.	2.0	22
88	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803.	6.7	22
90	Real-World Effectiveness of Sotrovimab and Remdesivir for Early Treatment of High-Risk Hospitalized COVID-19 Patients. SSRN Electronic Journal, 0, , .	0.4	0
92	The use of neutralizing monoclonal antibody in patients with COVID-19: a systematic review and meta-analysis. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2022, 68, 723-735.	0.7	0
93	Tixagevimabâ€“cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respiratory Medicine,the, 2022, 10, 972-984.	10.7	61
94	The crossâ€over of statistical thinking and practices: A pandemic catalyst. Pharmaceutical Statistics, 2022, 21, 778-789.	1.3	1
95	Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. International Journal of Infectious Diseases, 2022, 122, 585-592.	3.3	15
96	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell Host and Microbe, 2022, 30, 1231-1241.e6.	11.0	55
97	Monoclonal antibody therapies against SARS-CoV-2. Lancet Infectious Diseases, The, 2022, 22, e311-e326.	9.1	114
98	Management of Severe and Critical COVID-19 Infection with Immunotherapies. Infectious Disease Clinics of North America, 2022, , .	5.1	0
99	Monoclonals for patients hospitalised with COVID-19. Lancet Respiratory Medicine,the, 2022, 10, 928-930.	10.7	3
100	Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. Current Opinion in Infectious Diseases, 2022, 35, 280-287.	3.1	6
101	Main changes in the â€œcovid-19 in paediatricsâ€•clinical practice guideline. Anales De PediatrÃa (English) Tj ETQq1 1 0.784314 rgBT	0.2	0

#	Article	IF	Citations
102	Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial. Advances in Biological Regulation, 2022, 86, 100901.	2.3	9
103	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. Journal of Hepatology, 2022, 77, 1161-1197.	3.7	46
104	The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. Frontiers in Immunology, 0, 13, .	4.8	5
105	Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study. Clinical Infectious Diseases, 2023, 76, e172-e178.	5.8	54
106	Managing COVID-19 in pregnant women. Breathe, 2022, 18, 220019.	1.3	0
107	Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. Journal of Infectious Diseases, 2022, 227, 23-34.	4.0	21
108	Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for <scp>COVID</scp>â€19: The <scp>GIMEMA EMATO</scp>â€0321 study. British Journal of Haematology, 2022, 199, 54-60.	2.5	10
109	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet, The, 2022, 400, 359-368.	13.7	146
110	Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2023, 29, 13-21.	6.0	19
111	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. Journal of Clinical Medicine, 2022, 11, 4464.	2.4	13
112	Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic. Frontiers in Immunology, 0, 13, .	4.8	9
113	Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay. Diagnostic Microbiology and Infectious Disease, 2022, , 115788.	1.8	1
114	Treatments for the Infection by SARS-CoV-2. , 0, , .		0
115	Care of the Seriously Ill Patient with SARS CoV-2. Medical Clinics of North America, 2022, , .	2.5	1
116	Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19). American Journal of Perinatology, 0, , .	1.4	0
117	Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial. Journal of Infectious Diseases, 2023, 227, 206-210.	4.0	12
118	A review of clinical efficacy data supporting emergency use authorization for <scp>COVID</scp> â€19 therapeutics and lessons for future pandemics. Clinical and Translational Science, 0, , .	3.1	2
119	Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19. Annals of Internal Medicine, 2022, 175, 1266-1274.	3.9	12

#	Article	IF	Citations
120	Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19. PLoS ONE, 2022, 17, e0273223.	2.5	4
121	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). Journal of Intensive Medicine, 2022, 2, 199-222.	2.1	3
123	Nonproductive exposure of <scp>PBMCs</scp> to <scp>SARSâ€CoV</scp> â€2 induces cellâ€intrinsic innate immune responses. Molecular Systems Biology, 2022, 18, .	7.2	7
124	Vertical anti-SARS-CoV-2 monoclonal antibody transfer from mothers to HIV-exposed and unexposed infants. Aids, 2022, 36, 1613-1615.	2.2	0
125	COVID-19 in patients with B cell immune deficiency. Journal of Immunological Methods, 2022, 510, 113351.	1.4	1
126	Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies. Internal Medicine, 2022, 61, 3703-3708.	0.7	3
127	Effect of casirivimab-imdevimab on mild COVID-19 patients with diabetes in reducing oxygen supplementation at 28 days: an observational study. International Journal of Research in Medical Sciences, 2022, 10, 1983.	0.1	0
128	Presence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus-2 on Admission Is Associated With Decreased Mortality in COVID-19 Critical Illness. , 2022, 4, e0754.		1
129	The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. Annals of Internal Medicine, 2022, 175, 1401-1410.	3.9	32
130	Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era. Cancers, 2022, 14, 4252.	3.7	3
131	What progress has been made in treatment of immunocompromised COVID-19 patients?. Infectious Diseases Now, 2022, 52, S12-S15.	1.6	2
132	Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy. Expert Opinion on Drug Safety, 2022, 21, 1137-1141.	2.4	2
133	Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. MBio, 2022, 13, .	4.1	8
134	Safety and effectiveness of RBD-specific polyclonal equine F(abÂ´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. PLoS ONE, 2022, 17, e0274796.	2.5	0
136	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. ERJ Open Research, 0, , 00236-2022.	2.6	2
137	Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood, 2022, 140, 2773-2787.	1.4	40
138	Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective. Vaccines, 2022, 10, 1612.	4.4	14
139	Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group. Respiratory Research, 2022, 23, .	3.6	12

#	Article	IF	Citations
140	Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort. Infection, 2023, 51, 851-858.	4.7	4
141	Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study. Journal of Infection, 2022, 85, 545-556.	3.3	20
142	Care for adults with <scp>COVID</scp> â€19: living guidelines from the National <scp>COVID</scp> â€19 Clinical Evidence Taskforce. Medical Journal of Australia, 2022, 217, 368-378.	1.7	8
143	COVID-19-associated AKI. Current Opinion in Critical Care, 2022, 28, 630-637.	3.2	14
144	Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies. Transplant International, 0, 35, .	1.6	4
145	Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients. Frontiers in Immunology, 0, 13, .	4.8	6
146	Managing Covid-19 in patients with heart failure: current status and future prospects. Expert Review of Cardiovascular Therapy, 2022, 20, 807-828.	1.5	0
147	An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. Expert Opinion on Pharmacotherapy, 2022, 23, 1695-1700.	1.8	1
148	Japanese rapid/living recommendations on drug management for <scp>COVID</scp>â€19: updated guidelines (July 2022). Acute Medicine & Surgery, 2022, 9, .	1.2	6
149	Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open, 2022, 8, e002575.	3.8	3
150	Dose optimisation and scarce resource allocation: two sides of the same coin. BMJ Open, 2022, 12, e063436.	1.9	5
151	Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Frontiers in Immunology, 0, 13, .	4.8	8
152	Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. Nature Communications, 2022, 13, .	12.8	33
153	Efficacy and safety of sotrovimab in patients with COVIDâ€19: A rapid review and metaâ€analysis. Reviews in Medical Virology, 2022, 32, .	8.3	17
154	Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19. Trials, 2022, 23, .	1.6	0
155	Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies. MBio, 0, , .	4.1	3
157	Therapeutic advances in COVID-19. Nature Reviews Nephrology, 2023, 19, 38-52.	9.6	67
159	Neutralizing antibodies for SARS-CoV-2 infection. Revista Espanola De Quimioterapia, 2022, 35, 16-19.	1.3	0

#	Article	IF	Citations
160	Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitaminâ€“Drug Interactions Exist?. Life, 2022, 12, 1654.	2.4	1
161	AMMI Canada Practice Point on the treatment of acute COVID-19 in pediatrics. Jammi, 0, , .	0.5	0
162	B-cell malignancies and COVID-19: a narrative review. Clinical Microbiology and Infection, 2023, 29, 332-337.	6.0	7
163	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Life, 2022, 12, 1758.	2.4	9
164	Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. European Journal of Medicinal Chemistry, 2022, 244, 114857.	5.5	7
165	The impact of obesity on the outcome of severe SARS-CoV-2 ARDS in a high volume ECMO centre: ECMO and corticosteroids support the obesity paradox. Journal of Critical Care, 2022, 72, 154162.	2.2	10
166	Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients. Current Opinion in Organ Transplantation, 2022, 27, 269-276.	1.6	5
167	Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies. Nature Communications, 2022, 13, .	12.8	9
169	Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. Cureus, 2022, , .	0.5	1
170	Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Critical Care, 2022, 26, .	5.8	16
171	Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2â€“specific memory T cell responses. JCI Insight, 2022, 7, .	5.0	5
172	Immediate hypersensitivity reactions to antiâ€SARSâ€CoVâ€2 neutralizing monoclonal antibodies: A realâ€life experience. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 1119-1120.	5.7	1
173	Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge. Vaccines, 2022, 10, 1895.	4.4	3
174	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. Frontiers in Immunology, 0, 13, .	4.8	14
175	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. Frontiers in Immunology, 0, 13, .	4.8	3
176	Antiviral Treatment of COVID-19 Pneumonia. Clinics in Chest Medicine, 2022, , .	2.1	0
177	A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza. Transfusion Medicine, 2023, 33, 26-38.	1.1	1
178	Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands. Open Forum Infectious Diseases, 2022, 9, .	0.9	4

#	Article	IF	Citations
179	Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?. Clinical Infectious Diseases, 2022, 75, S530-S540.	5.8	4
182	Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment. Clinical Drug Investigation, 2023, 43, 13-22.	2.2	1
183	Inhalable neutralizing antibodies â€“ promising approach to combating respiratory viral infections. Trends in Pharmacological Sciences, 2023, 44, 85-97.	8.7	8
184	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. European Journal of Cancer, 2023, 181, 102-118.	2.8	2
185	Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. Science Advances, 2022, 8, .	10.3	9
187	Realâ€world effectiveness of sotrovimab and remdesivir for early treatment of highâ€risk hospitalized COVIDâ€19 patients:ÂAÂpropensity score adjusted retrospective cohort study. Journal of Medical Virology, 2023, 95, .	5.0	4
188	Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19. Frontiers in Medicine, 0, 9, .	2.6	19
189	Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals. Oxford Open Immunology, 2023, 4, .	2.8	1
190	Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2023, 7, 109-121.	2.4	2
193	Is the 4C Score Still a Valid Item to Predict In-Hospital Mortality in People with SARS-CoV-2 Infections in the Omicron Variant Era?. Life, 2023, 13, 183.	2.4	4
194	Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort. Journal of Clinical Medicine, 2023, 12, 864.	2.4	4
195	Treatment of <scp>COVID</scp>â€19 patients with a <scp>SARSâ€CoV</scp>â€2â€specific <scp>siRNA</scp>â€peptide dendrimer formulation. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 1639-1653.	5.7	5
196	Investigation on the Essential Oils of the Achillea Species: From Chemical Analysis to the In Silico Uptake against SARS-CoV-2 Main Protease. Life, 2023, 13, 378.	2.4	0
197	Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	4
198	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. JAMA Network Open, 2023, 6, e2253301.	5.9	0
199	Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU). PLoS ONE, 2023, 18, e0280745.	2.5	6
200	Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study. International Journal of Infectious Diseases, 2023, 131, 155-161.	3.3	4
201	Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nature Reviews Immunology, 2023, 23, 720-734.	22.7	8

#	Article	IF	Citations
202	Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience. Heliyon, 2023, 9, e13126.	3.2	1
203	Use of Sotrovimab in 14 Children with COVID-19: A Single-center Experience. Pediatric Infectious Disease Journal, 2023, 42, e61-e63.	2.0	2
204	Estimating the global impact of coronavirus disease 2019 on people living with HIV. Current Opinion in Infectious Diseases, 2023, 36, 20-25.	3.1	2
205	Do Anti-SARS-CoV-2 Monoclonal Antibodies Have an Impact on Pregnancy Outcome? A Systematic Review and Meta-Analysis. Vaccines, 2023, 11, 344.	4.4	2
206	Monoclonal Antibodies in Hospitalised Patients with COVID-19: The Role of SARS-COV-2 Serostatus in an Evolving Pandemic. Infectious Diseases and Therapy, 2023, 12, 735-747.	4.0	1
207	Insights into COVID-19-associated critical illness: a narrative review. Annals of Translational Medicine, 2023, 11, 220-220.	1.7	2
208	The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19. Journal of Pharmaceutical Innovation, 2023, 18, 1194-1212.	2.4	2
209	OligoBinders: Bioengineered Soluble Amyloid-like Nanoparticles to Bind and Neutralize SARS-CoV-2. ACS Applied Materials & Interfaces, 2023, 15, 11444-11457.	8.0	2
210	French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19). Therapie, 2023, , .	1.0	0
211	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respiratory Medicine,the, 2023, 11, 453-464.	10.7	35
212	Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. Frontiers in Immunology, 0, 14, .	4.8	3
213	Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population. BMC Infectious Diseases, 2023, 23, .	2.9	1
214	Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. EClinicalMedicine, 2023, 57, 101898.	7.1	1
215	Cancer, more than a â€œCOVID-19 co-morbidityâ€. Frontiers in Oncology, 0, 13, .	2.8	2
216	Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. BMC Clinical Pathology, 2023, 16, 2632010X2311612.	1.7	3
217	Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews. Expert Review of Vaccines, 2023, 22, 341-365.	4.4	4
218	Prognostic value of severe acute respiratory syndrome coronavirusâ€2 viral load and antibodies in patients hospitalized with <scp>COVID</scp>â€19. Clinical and Translational Science, 2023, 16, 1049-1062.	3.1	2
219	Case Studies of Platform Trials. , 2023, , 115-126.		0

#	Article	IF	Citations
220	Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America, 2023, 37, 475-493.	5.1	1
221	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nature Communications, 2023, 14, .	12.8	31
222	The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors. Journal of Infectious Diseases, 2023, 228, 245-250.	4.0	1
223	COVID and kidney: The struggle so far. International Journal of Applied & Basic Medical Research, 2023, 13, 1.	0.5	0
224	Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients with COVID-19: A Post-Hoc Analysis in a Phase 1/2/3 Double-Blind Trial. Open Forum Infectious Diseases, 0, , .	0.9	0
225	Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery, 2023, 22, 449-475.	46.4	112
227	How Electronic Medical Record Integration Can Support More Efficient Critical Care Clinical Trials. Critical Care Clinics, 2023, , .	2.6	0
228	Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2023, 42, 77-94.	1.6	2
229	Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient Patients. Journal of Clinical Immunology, 2023, 43, 1083-1092.	3.8	3
230	Comprehensive, Comparative Evaluation of 35 Manual SARS-CoV-2 Serological Assays. Microbiology Spectrum, 2023, 11, .	3.0	1
231	Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis. Journal of Infection, 2023, 87, 82-84.	3.3	1
232	Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses. BMC Infectious Diseases, 2023, 23, .	2.9	2
233	Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nature Communications, 2023, 14, .	12.8	6
235	COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants. Immune Network, 2023, 23, .	3.6	3
236	Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center. Medical Journal Armed Forces India, 2023, , .	0.8	0
237	Successful Kidney Transplantation of Two Patients with Donors Positive for Severe Acute Respiratory Syndrome Coronavirus Infection. OBM Transplantation, 2023, 07, 1-12.	0.2	0
238	Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study. Frontiers in Pharmacology, 0, 14, .	3.5	1
239	Tocilizumab versus anakinra in COVID-19: results from propensity score matching. Frontiers in Immunology, 0, 14, .	4.8	1

#	Article	IF	Citations
241	Anthracyclines inhibit SARS-CoV-2 infection. Virus Research, 2023, 334, 199164.	2.2	1
242	Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations. International Journal of Infectious Diseases, 2023, 134, 228-238.	3.3	2
243	Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study. Vaccine, 2023, 41, 5195-5200.	3.8	0
244	Pharmacological and Non-pharmacological Intervention in Epidemic Prevention and Control: A Medical Perspective. Lecture Notes on Data Engineering and Communications Technologies, 2023, , 573-582.	0.7	0
245	Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study. Intensive Care Medicine Experimental, 2023, 11, .	1.9	2
246	Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study. Terapevticheskii Arkhiv, 2023, 95, 494-499.	0.8	0
247	Use of Monoclonal Antibodies in Pregnant Women Infected by COVID-19: A Case Series. Microorganisms, 2023, 11, 1953.	3.6	0
248	Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study. Pharmacological Reports, 2023, 75, 1254-1264.	3.3	0
249	Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials. Scientific Reports, 2023, 13, .	3.3	1
250	Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis. Journal of Microbiology, Immunology and Infection, 2023, 56, 909-920.	3.1	1
251	Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects. Biosafety and Health, 2023, 5, 272-279.	2.7	0
252	Respiratory syncytial virusâ€“approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors. Journal of Biological Chemistry, 2023, 299, 105270.	3.4	0
253	GRADE concept 6: a novel application of external indirect evidence into GRADE ratings of evidence certainty in network meta-analysis. Journal of Clinical Epidemiology, 2023, 163, 95-101.	5.0	1
254	Blood and blood treatments. Side Effects of Drugs Annual, 2023, , .	0.6	0
255	Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis. Health Technology Assessment, 0, , 1-92.	2.8	0
256	Effect of swine glyco-humanized polyclonal neutralizing antibody on survival and respiratory failure in patients hospitalized with severe COVID-19: A Randomized, placebo-controlled Trial. Open Forum Infectious Diseases, 0, , .	0.9	0
257	Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Diabetes and Endocrinology,the, 2023, 11, 905-914.	11.4	2
258	Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	2

#	Article	IF	Citations
259	Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study. Viruses, 2023, 15, 2180.	3.3	2
260	Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial. , 2023, 2, e000427.		3
261	Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis. Lancet Microbe, The, 2023, 4, e883-e892.	7.3	2
262	Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma. MBio, 0, , .	4.1	1
264	Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. Journal of Infectious Diseases, 0, , .	4.0	0
266	Clinical course and management of COVID-19 in the era of widespread population immunity. Nature Reviews Microbiology, 2024, 22, 75-88.	28.6	1
267	An Update on SARS-CoV-2 Clinical Trial Resultsâ€"What We Can Learn for the Next Pandemic. International Journal of Molecular Sciences, 2024, 25, 354.	4.1	1
268	Comparison of effect estimates between preprints and peer-reviewed journal articles of COVID-19 trials. BMC Medical Research Methodology, 2024, 24, .	3.1	1
269	Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child and Adolescent Health, 2024, 8, 190-200.	5.6	0
270	Global landscape ofÂCOVID-19 research: a visualization analysis of randomized clinical trials. Clinical and Experimental Medicine, 2024, 24, .	3.6	0
271	Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 2024, 15, .	12.8	1
272	Deciphering Fc-effector functions against SARS-CoV-2. Trends in Microbiology, 2024, , .	7.7	0
273	Investigational pharmacological agents for the treatment of ARDS. Expert Opinion on Investigational Drugs, 2024, 33, 243-277.	4.1	0
274	Clinical and Virological Outcome of Monoclonal Antibody Therapies Across Severe Acute Respiratory Syndrome Coronavirus 2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study. Clinical Infectious Diseases, 0, , .	5.8	0
275	A Short Update on the Use of Monoclonal Antibodies in COVID-19. AAPS Journal, 2024, 26, .	4.4	0
276	Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVIDâ€19: An early phase 1 descriptive study. Health Science Reports, 2024, 7, .	1.5	0
277	Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors. , 2024, 2, 48-55.		0
278	Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent. Pathogens, 2024, 13, 272.	2.8	0

#	Article	IF	Citations
279	Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia. Frontiers in Medicine, 0, 11, .	2.6	0
280	Decoding the historical tale: COVID-19 impact on haematological malignancy patientsâ€"EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine, 2024, 71, 102553.	7.1	0